ScreenerHero

FBIOPFortress Biotech, Inc.

NAS · US · Healthcare · Biotechnology · fortressbiotech.com
18.30USD+0.52%Mkt Cap: —P/E: —

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule fo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap—
Enterprise Value508.01M $
Revenue (TTM)68.47M $
Gross Profit42.34M $
Net Income (TTM)6.82M $
Revenue/Share2.252 USD
Last Price18.30 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees78
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-20.67
EV/Revenue7.42
P/S—
P/B3.71
EPS (TTM)-0.86
EPS (Forward)—
52W Range
6.27079% of range21.43
52W High21.43 USD
52W Low6.270 USD
Profitability
Gross Margin66.92%
Oper. Margin-53.46%
EBITDA Margin-35.90%
Profit Margin10.77%
ROE13.66%
ROA3.67%
Growth
Revenue Growth14.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-65.78M $
CapEx (TTM)—
FCF Margin-24.66%
FCF Yield—
Net Debt-143.26M $
Net Debt/EBITDA5.83
Balance Sheet
Debt/Equity1.49
Current Ratio3.96
Quick Ratio3.76
Book Value/Sh4.927 USD
Cash/Share5.894 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield14.44%
Payout Ratio—
Ex-Div DateJun 14, 2024
Pay DateJun 30, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.56.68M
Float23.22M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio0.0d
Shares Short0
Short (prev mo.)751
Technical
SMA 5019.37 (-5.5%)
SMA 20013.95 (+31.2%)
Beta1.21
S&P 52W Chg18.16%
Avg Vol (30d)11.05K
Avg Vol (10d)12.67K
Technical Indicators
RSI (14)38.6
MACD-0.1603
MACD Signal-0.0411
MACD Hist.-0.1192
BB Upper19.95 USD
BB Middle18.97 USD
BB Lower17.99 USD
BB Width10.32%
ATR (14)0.5243 USD
Vol Ratio (20d)0.73x